Browse studies
Find your next paid study
16 recruiting studies matching your filters
Phase 1
A Phase 1 Study of SynKIR-310, Autologous T Cells Transduced With CD19 KIR-CAR, in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administ…
B Cell LymphomaNHL, AdultMantle Cell Lymphoma+23 more
Estimated
~$10 – $8,750
Verismo TherapeuticsNCT06544265
Phase 2
A Phase 2 Trial of Emapalumab for the Prevention of CAR-T Cell Associated Toxicities
This research study involves assessing the impact of emapalumab as preventative management of CAR-T related cytokine release syndrome in participants with Non-…
Large B-cell LymphomaRelapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin Lymphoma+4 more
Estimated
~$10 – $7,500
Marcela V. Maus, M.D.,Ph.D.NCT06550141
Phase 1
A Phase I Study of Bivalent CD79b and CD19 Directed CAR T Cells in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma
This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side eff…
Non-hodgkin LymphomaRelapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin Lymphoma+7 more
Estimated
~$10 – $7,500
Marcela V. Maus, M.D.,Ph.D.NCT06026319
Phase 2
TPG: a Phase 2 Trial of Polatuzumab Vedotin, Glofitamab, and Tafasitamab as Chemotherapy-sparing First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
This is a single-center, phase 2, open-label clinical trial of a novel combination of polatuzumab vedotin, glofitamab, and tafasitamab (TPG) as first-line trea…
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaLymphoma+1 more
Estimated
~$10 – $6,250
Brown UniversityNCT07502872